Quantinno Capital Management LP Acquires 13,499 Shares of Sanofi (NASDAQ:SNY)

Quantinno Capital Management LP grew its position in Sanofi (NASDAQ:SNY - Free Report) by 15.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 98,876 shares of the company's stock after buying an additional 13,499 shares during the period. Quantinno Capital Management LP's holdings in Sanofi were worth $5,698,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company's stock worth $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company's stock valued at $121,605,000 after purchasing an additional 2,306,286 shares during the period. Jennison Associates LLC raised its stake in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock valued at $109,753,000 after purchasing an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock valued at $82,366,000 after purchasing an additional 1,424,289 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company's stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

NASDAQ:SNY traded down $0.05 on Friday, hitting $48.46. The company's stock had a trading volume of 1,590,336 shares, compared to its average volume of 2,300,876. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a fifty day moving average of $51.90 and a two-hundred day moving average of $52.09. The firm has a market capitalization of $122.98 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 1.22 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the previous year, the business earned $2.55 EPS. The company's quarterly revenue was up 12.3% on a year-over-year basis. Research analysts predict that Sanofi will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on SNY shares. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a research note on Friday. Citigroup raised Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.